Physician profile
David Makil
NPI 1679554174
$976.12
in general payments reported to CMS, 2019-2025
14 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.02 · 2020: $78.26 · 2021: $32.19 · 2022: $50.07 · 2023: $359 · 2024: $190 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $245.72 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $124.21 | 2019-2024 | Lokelma, Farxiga |
| Alexion Pharmaceuticals, INC. | $112.15 | 2022-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $106.87 | 2019-2023 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.62 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $81.29 | 2025 | |
| Novo Nordisk INC | $42.10 | 2025 | Ozempic |
| Travere Therapeutics, INC. | $38.93 | 2024 | |
| Akebia Therapeutics INC | $30.11 | 2019-2023 | Auryxia |
| Aurinia Pharma U.S., INC. | $25.36 | 2024 | Lupkynis |
| Lilly USA, LLC | $23.47 | 2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $21.25 | 2023 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $16.17 | 2021 | |
| Nxstage Medical, INC. | $12.87 | 2023 | Nxstage Pureflow Solution, Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Makil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.